Similar Articles
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Miraç Ayşen Ünsal
DOI: 10.4274/tnd.2019.00187
Issue: 2019, Volume 25 - Issue 1
0
1251
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir
DOI: 10.4274/tnd.62144
Issue: 2017, Volume 23 - Issue 4
0
1078
Weight Loss and Fingolimod
Nefati Kıylıoğlu
DOI: 10.4274/tnd.87528
Issue: 2017, Volume 23 - Issue 4
0
798
The effect of fingolimod on complete blood count, lipid panel, and relationship with clinicoradiologic features in patients with multiple sclerosis
Furkan Sarıdaş, Sarah Hamide Lazrak, Emine Rabia Koç, Güven Özkaya, Ömer Faruk Turan
DOI: 10.55697/tnd.2025.213
Issue: 2025, Volume 31 - Issue 4
187
188